Read More »
Drug hopes to treat anaemia caused by chronic kidney disease
GlaxoSmithKline is now enrolling patients into a phase III trial of daprodustat, a drug for treating anaemia associated with chronic kidney disease (CKD)
In the presence of reduced oxygen levels in the blood,Daprodustat is believed to turn on the body’s machinery for producing red blood cells and thus, could provide an alternative to inject able anaemia treatments such as blood cell stimulator erythropoietin (EPO).
GSK’s pivotal trials programme includes two studies involving patients with CKD-related anaemia, who will either be switched from treatment with EPO or who will not have previously been treated for the condition. ASCEND-D will enrol around 3,000 patients on dialysis who have switched from EPO, while ASCEND-ND will involve 4,500 subjects who are not on dialysis and will either be EPO-naïve or switchers.